Year: 2013
Type: article
Abstract: n this issue of HEPATOLOGY, Noureddin et al. describe an innovative application of an emerging magnetic resonance imaging (MRI)-based biomarker, proton density fat-fraction (PDFF), for quantification of hepatic steatosis in patients with nonalcoholic steatohepatitis (NASH). 1 In this study, 50 patients with biopsy-proven NASH were enrolled in a randomized double-blinded placebo-controlled trial.Patients were randomized to receive placebo or colesevelam, an agent known to reduce elevated lowdensity lipoprotein (LDL) and to improve glycemic control in adults with type II diabetes.The authors performed cross-sectional comparisons of MRI-derived PDFF with MR spectroscopy (MRS)-derived PDFF and nontargeted liver biopsy, at baseline and after 24 weeks of treatment.This study demonstrated excellent agreement and correlation between MRI and MRS, and also demonstrated excellent correlation between both MRI and MRS with histology-derived steatosis grade.Perhaps most interesting, the authors determined that longitudinal changes in MRI-derived PDFF was more sensitive to detection of changes in liver fat than biopsy, with changes in liver fat paralleling changes in body weight and serum aminotransferases between baseline and week 24.These exciting results demonstrate the utility of quantitative MRI methods for treatment monitoring using a novel, noninvasive imaging-based biomarker of hepatic steatosis.Biopsy is and will remain the clinical gold standard for the diagnosis, grading, and staging of diffuse liver disease.However, emerging imaging-based biomarkers of diffuse liver disease, such as MRI-derived PDFF,
Source: Hepatology
DOI: 10.1002/hep.26543
Author: Scott B. Reeder
Institution: University of Wisconsin–Madison
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: OSI, proton density fat fraction, nonalcoholic steatohepatitis, quantitative MRI, MR spectroscopy, non-invasive biomarkers, colesevelam, liver biopsy, treatment monitoring, liver fat quantification, type 2 diabetes, transaminases, weight change, liver fibrosis, liver inflammation, ballooning degeneration
Open Access status: bronze
OpenAlex ID: W2054143624
